Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.
about
Gadolinium contrast media during pregnancy and lactationNephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices.Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future PerspectivesNephrogenic systemic fibrosis: a concise review for cardiologists.Hyperintense Dentate Nuclei on T1-Weighted MRI: Relation to Repeat Gadolinium AdministrationGadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd³⁺ to the glycosaminoglycan heparin.Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands.Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.Primer on gadolinium chemistry.Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imagingQuantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnosticsThe fate of Gd and chelate following intravenous injection of gadodiamide in rats.Blood oxygen level-dependent and perfusion magnetic resonance imaging: detecting differences in oxygen bioavailability and blood flow in transplanted kidneysMR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.Fibroblast response to gadolinium: role for platelet-derived growth factor receptorResponses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects.The degradation and clearance of Poly(N-hydroxypropyl-L-glutamine)-DTPA-Gd as a blood pool MRI contrast agent.Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats.Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.Gadolinium retention in the body: what we know and what we can do.Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional studyPathophysiology of gadolinium-associated systemic fibrosisSafety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million ApplicationsQuantitative MR measures of intrarenal perfusion in the assessment of transplanted kidneys: initial experience.Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model.Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.MR imaging in multiple sclerosis: review and recommendations for current practice.Magnetic resonance imaging evaluation of renal structure and function related to disease: technical review of image acquisition, postprocessing, and mathematical modeling steps.Update on nephrogenic systemic fibrosis: are we making progress?Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.Nephrogenic systemic fibrosis: concepts and perspectives.Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.Gadolinium and nephrogenic systemic fibrosis: an update.The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.
P2860
Q22065340-997913CB-35AE-45A5-9FD0-B7400683C159Q24602293-6B938951-B5D2-4DAC-803C-66F6CDA7651AQ26751073-5F8F2E67-B13D-4685-8297-6D6163EE419EQ26774810-7ED51E6F-0406-4251-A8DD-B34F1A2A2041Q28972564-09280AAC-E6A7-4004-818A-4C6A691BC19DQ30383185-8326BBF7-0A1B-4CBE-8F8B-E5613DD2338CQ30583956-D52C2451-8668-431E-8FD8-D0A072EAB02AQ30604750-44CC145A-0D1F-458E-98A2-89099701CF59Q31045014-0A9BD2B8-2C1C-4F96-A4D7-697505D6DA10Q33516622-C2F8772B-8E6B-4B42-8863-0F74F1221A7EQ33655413-217590C5-7BED-407B-9110-99332B45F47CQ33768662-1B713A93-A768-4A6B-9717-2FF83075A7CCQ33778968-2C248BE7-C0FB-4AD5-A05A-AE080139BB6EQ33894429-AF53FE84-D29C-4679-8E4F-A428B21A8F20Q33899096-2C78895B-8700-44A6-AE56-FE83DC01FDAFQ33936568-3489234C-AD2B-4696-BEDD-93EA81D095FDQ34053148-16AA2498-1CDC-4F0D-9F60-12CF65D94BBDQ35187914-B7EB800B-110C-42ED-AE1D-C6AAE2969B0EQ35187986-2610190D-9556-410F-8320-B31725ADB65FQ35973677-AC632999-ED7E-4C95-9992-7DD0468E310DQ36027601-FCB1E961-97BD-4B0C-B2B6-02525F5C032DQ36316226-7B604D2C-F7C5-42F3-9BF0-BCC602B69D5AQ36329191-F6723D11-071C-43CA-9B39-AF03FCC4C6EEQ36470970-CE4141C4-BBF9-4A38-9ACA-61BB8B26E973Q36510352-526E4501-33C4-4BB8-9323-BECCFB6EE82DQ37092639-FFE59855-F075-43F0-880F-051071E296F1Q37139482-7292D84C-ED18-45D7-A989-54E416D2E42CQ37170996-33273B67-1910-45E0-9F7F-B4D0CDF187B6Q37359005-4E052DAF-618E-4448-A2EA-66A0749CED27Q37404908-38B1E163-61E4-4383-B3DC-0D7E486FBC8DQ37486093-FC2541EC-F544-4E52-A43F-7360A12C0119Q37658010-BBE2CE19-60B1-425E-A8CD-FA4D089F09E2Q37876831-6E9E367E-6C6C-4B00-B78F-1592F59C1735Q37877286-03EBC43A-6CD0-41A9-ABFF-C5D871DE4BE1Q38032230-AB8148B1-EA04-457D-92B7-188AF27538CCQ38034645-089DAF55-B26F-4961-8518-CAF18DED5AB5Q38084164-A9D52909-0403-4707-8A3F-B6885E9D80B9Q38154533-E87DA76D-944A-4135-B698-4E7AFA66240AQ38254508-4C4AD487-F02A-4686-8557-90A1CC00643EQ38570145-5EB0C15F-6EDD-43EA-A40A-4D301F443A48
P2860
Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Preclinical investigation to c ...... ystemic fibrosis-like lesions.
@en
Preclinical investigation to c ...... ystemic fibrosis-like lesions.
@nl
type
label
Preclinical investigation to c ...... ystemic fibrosis-like lesions.
@en
Preclinical investigation to c ...... ystemic fibrosis-like lesions.
@nl
prefLabel
Preclinical investigation to c ...... ystemic fibrosis-like lesions.
@en
Preclinical investigation to c ...... ystemic fibrosis-like lesions.
@nl
P2093
P1433
P1476
Preclinical investigation to c ...... ystemic fibrosis-like lesions.
@en
P2093
Fred Siegmund
Hanns-Joachim Weinmann
Heribert Schmitt-Willich
Hubertus Pietsch
Jakob Walter
Martin A Sieber
Philipp Lengsfeld
Sven Golfier
Thomas Frenzel
P2888
P304
P356
10.1007/S00330-008-0977-Y
P407
P577
2008-06-11T00:00:00Z